文献速递头颈与中枢神经肿瘤

鼻咽癌诱导化疗后减体积放疗对比常规体积放疗:一项开放标签、非劣效、多中心、随机3期试验

Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.
PubMed 文献 · CA Cancer J Clin · 2025-02-19

该多中心非劣效随机3期试验纳入完成诱导化疗的局部区域晚期鼻咽癌患者445例,1:1随机接受基于化疗后肿瘤体积的减体积放疗或基于化疗前体积的常规放疗。中位随访40.4个月,3年局部区域无复发生存率减体积组91.5%对常规组91.2%,差值0.3%(95%CI -4.9%至5.5%),减体积组3-4级放疗相关毒性更低且生活质量更优。

要点

  • 减体积放疗3年局部区域无复发生存率91.5%对常规体积91.2%,差值0.3%(95%CI -4.9%至5.5%),达到非劣效。
  • 减体积组3-4级急性口腔黏膜炎19.8%对34.1%,晚期中耳炎9.5%对20.9%,晚期口干3.6%对9.5%。
  • 减体积组在整体健康状况、躯体功能、情绪功能、口干和唾液黏稠方面生活质量更优。

核心结论

  • 本试验中减体积放疗在局部区域无复发生存方面非劣效于常规体积放疗,且与更低毒性和改善的生活质量相关。

研究设计与样本

  • 多中心、非劣效、随机对照3期试验,纳入完成诱导化疗的局部区域晚期鼻咽癌患者。
  • 2020年8月7日至2022年5月27日随机分配445例患者至化疗后体积组(n=225)或化疗前体积组(n=220)。
  • 主要终点为局部区域无复发生存,非劣效界值8%;次要终点包括不良事件和生活质量。

主要发现

  • 接受根治剂量的平均体积化疗后体积组为66.6 cm3,化疗前体积组为80.9 cm3。
  • 中位随访40.4个月,3年局部区域无复发生存率化疗后体积组91.5%对化疗前体积组91.2%,差值0.3%(95%CI -4.9%至5.5%)。
  • 3-4级放疗相关毒性发生率化疗后体积组更低,包括急性口腔黏膜炎(19.8% vs 34.1%)、晚期中耳炎(9.5% vs 20.9%)和晚期口干(3.6% vs 9.5%)。
  • 化疗后体积组在整体健康状况、躯体功能、情绪功能、口干和唾液黏稠方面的生活质量更优。

关键数值与推荐

  • 主要终点局部区域无复发生存非劣效界值为8%。
  • 3年局部区域无复发生存率化疗后体积组91.5%对化疗前体积组91.2%,差值0.3%(95%CI -4.9%至5.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the efficacy and safety of reduced-volume radiotherapy is uncertain. METHODS: In this multi-center, noninferiority, randomized, controlled trial, patients with LANPC who completed IC were randomly assigned (1:1) to receive reduced-volume radiotherapy based on post-IC tumor volume (Post-IC group) or conventional volume radiotherapy based on pre-IC tumor volume (Pre-IC group). The primary endpoint was locoregional relapse-free survival, with a noninferiority margin of 8%. Secondary endpoints comprised adverse events, and quality of life (QoL). RESULTS: Between August 7, 2020, and May 27, 2022, 445 patients were randomly assigned to Post-IC (n = 225) or Pre-IC (n = 220) groups. The average volume receiving radical dose was 66.6 cm3 in Post-IC group versus 80.9 cm3. After a median follow-up of 40.4 months, the 3-year locoregional relapse-free survival was 91.5% in the Post-IC group versus 91.2%, with a difference of 0.3% (95% confidence interval -4.9% to 5.5%). The incidence of grade 3-4 radiation-related toxicity was lower in the Post-IC group including: acute mucositis (19.8% vs 34.1%), late otitis media (9.5% vs 20.9%) and late dry month (3.6% vs 9.5%). The Post-IC group had better QoL for global health status, physical functioning, emotional functioning, dry mouth and sticky saliva. CONCLUSIONS: In this trial, reduced-volume radiotherapy was noninferior to conventional volume radiotherapy in locoregional relapse-free survival, and was associated with lower toxicities and improved QoL. (ClinicalTrials.gov identifier NCT04384627).

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Tang LL, Chen L, Xu GQ, et al. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025. PMID: 39970442. doi:10.3322/caac.21881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。